PMID-sentid	Pub_year	Sent_text	compound_name	comp_offset	prot_official_name	organism	prot_offset
30609543-2	2019	In this work, a simple and reproducible SERS substrate combining the properties of multi-walled carbon nanotubes (MWCNTs) and gold nanoparticles (AuNPs), is proposed for the determination and quantification of sulfapyridine in milk samples with a concentration range of 10-100 ng mL-1.	Sulfapyridine	210-223	L1 cell adhesion molecule	Mus musculus	280-284
32456937-8	2020	The calibration graphs were linear over the concentration ranges of 0.06-50 mg L-1 for sulfamethoxazole, sulfamethazine and sulfapyridine.	Sulfapyridine	124-137	L1 cell adhesion molecule	Homo sapiens	79-82
12795783-8	2003	The polymorphism of N-acetyltransferase 2, an enzyme that metabolizes sulphapyridine, was also determined by polymerase chain reaction.	Sulfapyridine	70-84	N-acetyltransferase 2	Homo sapiens	20-41
29374256-6	2018	We identified sulfapyridine and propranolol with activity against CRH and COX-2 that deserve further study.	Sulfapyridine	14-27	corticotropin releasing hormone	Homo sapiens	66-69
29374256-6	2018	We identified sulfapyridine and propranolol with activity against CRH and COX-2 that deserve further study.	Sulfapyridine	14-27	prostaglandin-endoperoxide synthase 2	Homo sapiens	74-79
27181550-5	2016	A genetic analysis showed that he had polymorphisms of ABCG2 and NAT2, which could lead to high plasma concentrations of SASP and sulfapyridine.	Sulfapyridine	130-143	ATP binding cassette subfamily G member 2 (Junior blood group)	Homo sapiens	55-60
27181550-5	2016	A genetic analysis showed that he had polymorphisms of ABCG2 and NAT2, which could lead to high plasma concentrations of SASP and sulfapyridine.	Sulfapyridine	130-143	N-acetyltransferase 2	Homo sapiens	65-69
24394199-2	2014	Plasma levels of SSA and its metabolite sulphapyridine are influenced by common polymorphisms in genes that encode N-acetyl transferase 2 (NAT2) and ATP-binding cassette protein G2 (ABCG2).	Sulfapyridine	40-54	N-acetyltransferase 2	Homo sapiens	115-137
24394199-2	2014	Plasma levels of SSA and its metabolite sulphapyridine are influenced by common polymorphisms in genes that encode N-acetyl transferase 2 (NAT2) and ATP-binding cassette protein G2 (ABCG2).	Sulfapyridine	40-54	N-acetyltransferase 2	Homo sapiens	139-143
24394199-2	2014	Plasma levels of SSA and its metabolite sulphapyridine are influenced by common polymorphisms in genes that encode N-acetyl transferase 2 (NAT2) and ATP-binding cassette protein G2 (ABCG2).	Sulfapyridine	40-54	ATP binding cassette subfamily G member 2 (Junior blood group)	Homo sapiens	149-180
24394199-2	2014	Plasma levels of SSA and its metabolite sulphapyridine are influenced by common polymorphisms in genes that encode N-acetyl transferase 2 (NAT2) and ATP-binding cassette protein G2 (ABCG2).	Sulfapyridine	40-54	ATP binding cassette subfamily G member 2 (Junior blood group)	Homo sapiens	182-187
19560446-3	2009	We investigated the effects of genetic polymorphism of NAT2 on pharmacokinetic profiles of SASP and its two metabolites, sulfapyridine (SP) and N-acetylsufapyridine (AcSP).	Sulfapyridine	93-95	N-acetyltransferase 2	Homo sapiens	55-59
19560446-10	2009	CONCLUSION: Different NAT2 genotypes, leading to functional heterogeneity of NAT2, may affect pharmacokinetics of SP and AcSP.	Sulfapyridine	114-116	N-acetyltransferase 2	Homo sapiens	22-26
19560446-10	2009	CONCLUSION: Different NAT2 genotypes, leading to functional heterogeneity of NAT2, may affect pharmacokinetics of SP and AcSP.	Sulfapyridine	114-116	N-acetyltransferase 2	Homo sapiens	77-81
18167504-4	2008	In contrast, AUC(0-48) of sulfapyridine (SP) tended to be lower in subjects with the ABCG2-A allele as homozygosity.	Sulfapyridine	26-39	ATP binding cassette subfamily G member 2 (Junior blood group)	Homo sapiens	85-90
18167504-4	2008	In contrast, AUC(0-48) of sulfapyridine (SP) tended to be lower in subjects with the ABCG2-A allele as homozygosity.	Sulfapyridine	41-43	ATP binding cassette subfamily G member 2 (Junior blood group)	Homo sapiens	85-90
17377643-5	2007	RESULTS: Eleven patients (16%) experienced adverse effects from SASP, including nine cases of sulfapyridine (SP) dose-related adverse effects and two cases of hypersensitivity (skin rash).	Sulfapyridine	94-107	aspartic peptidase retroviral like 1	Homo sapiens	64-68
17377643-8	2007	CONCLUSIONS: The NAT2 gene polymorphism was not associated with susceptibility to IBD in Chinese populations, but the NAT2 slow acetylator genotypes were significantly associated with SP dose-related adverse effects of SASP in the treatment of IBD.	Sulfapyridine	184-186	N-acetyltransferase 2	Homo sapiens	118-122
17377643-8	2007	CONCLUSIONS: The NAT2 gene polymorphism was not associated with susceptibility to IBD in Chinese populations, but the NAT2 slow acetylator genotypes were significantly associated with SP dose-related adverse effects of SASP in the treatment of IBD.	Sulfapyridine	184-186	aspartic peptidase retroviral like 1	Homo sapiens	219-223
16284462-3	2005	METHODS: MDR1 genotyping was performed in a population of 139 HIV-1-positive patients followed during 72 weeks, as part of the previous study called ANRS 081 "Trianon".	Sulfapyridine	159-166	ATP binding cassette subfamily B member 1	Homo sapiens	9-13
15032315-4	2004	Plasma concentrations of SASP and its two metabolites, sulfapyridine (SP) and N-acetylsulfapyridine (AcSP), were estimated by HPLC.	Sulfapyridine	55-68	aspartic peptidase retroviral like 1	Homo sapiens	25-29
15032315-8	2004	NAT2 genotypes significantly affected both the plasma concentration ratios of SP to AcSP (SP/AcSP) and the efficacy of SASP (p < 0.05).	Sulfapyridine	78-80	N-acetyltransferase 2	Homo sapiens	0-4
22348441-2	2012	This study investigated their effect on the metabolism and pharmacokinetics of sulfasalazine (SSZ), a drug whose efficacy depends on metabolism by azoreductase (AR) in the gut microbiota to sulfapyridine (SP) and 5-acetylsalicylic acid (5-ASA).	Sulfapyridine	190-203	NAD(P)H quinone dehydrogenase 1	Rattus norvegicus	161-163
19817724-2	2010	AIM: To test the hypothesis that sulfasalazine (SASP) might have a synergistic beneficial effect in acute pouchitis, by combining the anti-inflammatory activity of 5-aminosalicylic Acid and the bacteriostatic effect of sulphapyridine.	Sulfapyridine	219-233	aspartic peptidase retroviral like 1	Homo sapiens	48-52
15909923-3	2004	There are some suggestions in the literature that the intestinal bacterial azo-reductases are involved in biotransformation of SAS into 5-aminosalicylic acid (5-ASA) and sulphapyridine (SP).	Sulfapyridine	170-184	tetraspanin 31	Homo sapiens	127-130
15909923-3	2004	There are some suggestions in the literature that the intestinal bacterial azo-reductases are involved in biotransformation of SAS into 5-aminosalicylic acid (5-ASA) and sulphapyridine (SP).	Sulfapyridine	186-188	tetraspanin 31	Homo sapiens	127-130
15909923-5	2004	No enzymatic systems presumably exist in Caco-2, which could be responsible for SAS metabolism, because after 72 h-incubation of cell cultures with 1 mM SAS, its metabolites i.e., 5-ASA and SP were not detected in cells, neither in culture media.	Sulfapyridine	190-192	tetraspanin 31	Homo sapiens	153-156
15909923-8	2004	The other metabolite of SAS i.e., SP, was not transformed in the human colon cancer cells at all.	Sulfapyridine	34-36	tetraspanin 31	Homo sapiens	24-27
12186410-0	2002	N-acetyltransferase 2 genotype-related sulfapyridine acetylation and its adverse events.	Sulfapyridine	39-52	N-acetyltransferase 2	Homo sapiens	0-21
12231210-8	2002	These data suggest that SASP may function to reduce inflammation in RA through the effects of its metabolite SP to reduce the secretion of the inflammatory chemokines IL-8, GROalpha, and MCP-1.	Sulfapyridine	26-28	C-X-C motif chemokine ligand 8	Homo sapiens	167-171
12231210-4	2002	SP had a significant effect in that it decreased RA synovial tissue explant secretion of IL-8 (22%), GROalpha (55%), and monocyte chemotactic protein-1 (MCP-1) (42%) (P < 0.05).	Sulfapyridine	0-2	C-X-C motif chemokine ligand 8	Homo sapiens	89-93
12231210-4	2002	SP had a significant effect in that it decreased RA synovial tissue explant secretion of IL-8 (22%), GROalpha (55%), and monocyte chemotactic protein-1 (MCP-1) (42%) (P < 0.05).	Sulfapyridine	0-2	C-X-C motif chemokine ligand 1	Homo sapiens	101-109
12231210-4	2002	SP had a significant effect in that it decreased RA synovial tissue explant secretion of IL-8 (22%), GROalpha (55%), and monocyte chemotactic protein-1 (MCP-1) (42%) (P < 0.05).	Sulfapyridine	0-2	C-C motif chemokine ligand 2	Homo sapiens	121-151
12231210-4	2002	SP had a significant effect in that it decreased RA synovial tissue explant secretion of IL-8 (22%), GROalpha (55%), and monocyte chemotactic protein-1 (MCP-1) (42%) (P < 0.05).	Sulfapyridine	0-2	C-C motif chemokine ligand 2	Homo sapiens	153-158
12231210-6	2002	In IL-1beta-stimulated RA synovial tissue fibroblasts, SASP significantly increased chemokine secretion, while SP significantly decreased IL-8 (24%) and GROalpha (21%) secretion (P < 0.05).	Sulfapyridine	57-59	interleukin 1 beta	Homo sapiens	3-11
12231210-8	2002	These data suggest that SASP may function to reduce inflammation in RA through the effects of its metabolite SP to reduce the secretion of the inflammatory chemokines IL-8, GROalpha, and MCP-1.	Sulfapyridine	26-28	C-X-C motif chemokine ligand 1	Homo sapiens	173-181
12231210-8	2002	These data suggest that SASP may function to reduce inflammation in RA through the effects of its metabolite SP to reduce the secretion of the inflammatory chemokines IL-8, GROalpha, and MCP-1.	Sulfapyridine	26-28	C-C motif chemokine ligand 2	Homo sapiens	187-192
12186410-1	2002	Sulfapyridine (SP), one of the metabolites of sulfasalazine (SASP), is further metabolized into N-acetylsulfapyridine (AcSP) by polymorphic N-acetyltransferase 2 (NAT2).	Sulfapyridine	0-13	aspartic peptidase retroviral like 1	Homo sapiens	61-65
12186410-1	2002	Sulfapyridine (SP), one of the metabolites of sulfasalazine (SASP), is further metabolized into N-acetylsulfapyridine (AcSP) by polymorphic N-acetyltransferase 2 (NAT2).	Sulfapyridine	0-13	N-acetyltransferase 2	Homo sapiens	140-161
12186410-1	2002	Sulfapyridine (SP), one of the metabolites of sulfasalazine (SASP), is further metabolized into N-acetylsulfapyridine (AcSP) by polymorphic N-acetyltransferase 2 (NAT2).	Sulfapyridine	0-13	N-acetyltransferase 2	Homo sapiens	163-167
12186410-1	2002	Sulfapyridine (SP), one of the metabolites of sulfasalazine (SASP), is further metabolized into N-acetylsulfapyridine (AcSP) by polymorphic N-acetyltransferase 2 (NAT2).	Sulfapyridine	15-17	aspartic peptidase retroviral like 1	Homo sapiens	61-65
12186410-1	2002	Sulfapyridine (SP), one of the metabolites of sulfasalazine (SASP), is further metabolized into N-acetylsulfapyridine (AcSP) by polymorphic N-acetyltransferase 2 (NAT2).	Sulfapyridine	15-17	N-acetyltransferase 2	Homo sapiens	140-161
12186410-1	2002	Sulfapyridine (SP), one of the metabolites of sulfasalazine (SASP), is further metabolized into N-acetylsulfapyridine (AcSP) by polymorphic N-acetyltransferase 2 (NAT2).	Sulfapyridine	15-17	N-acetyltransferase 2	Homo sapiens	163-167
12186410-3	2002	Herein, we investigated the relationship between NAT2 genotypes and the pharmacokinetics of SP in healthy Japanese subjects, as well as the adverse events of SASP in patients with inflammatory bowel disease (IBD).	Sulfapyridine	92-94	N-acetyltransferase 2	Homo sapiens	49-53
12186410-7	2002	The NAT2 genotypes were well-correlated with the plasma concentrations or urinary excretions of SP and AcSP in 8 healthy subjects, except for one Slow Type.	Sulfapyridine	96-98	N-acetyltransferase 2	Homo sapiens	4-8
11604271-1	2001	We found that N-acetylation polymorphism can be evaluated from the disposition kinetics of sulfapyridine (SP) and 5-aminosalicylic acid (5-ASA) and their acetylated metabolites generated by N-acetyltransferase (NAT2) after oral administration of salicylazosulfapyridine (SASP).	Sulfapyridine	106-108	N-acetyltransferase 2	Homo sapiens	211-215
12135032-1	2002	OBJECTIVES: 5-Aminosalicylate is metabolized in colonic mucosa by N-acetyltransferase 1 (NAT1), and sulfapyridine is metabolized in the liver by N-acetyltransferase 2 (NAT2).	Sulfapyridine	100-113	N-acetyltransferase 2	Homo sapiens	145-166
12135032-1	2002	OBJECTIVES: 5-Aminosalicylate is metabolized in colonic mucosa by N-acetyltransferase 1 (NAT1), and sulfapyridine is metabolized in the liver by N-acetyltransferase 2 (NAT2).	Sulfapyridine	100-113	N-acetyltransferase 2	Homo sapiens	168-172
11604271-1	2001	We found that N-acetylation polymorphism can be evaluated from the disposition kinetics of sulfapyridine (SP) and 5-aminosalicylic acid (5-ASA) and their acetylated metabolites generated by N-acetyltransferase (NAT2) after oral administration of salicylazosulfapyridine (SASP).	Sulfapyridine	91-104	N-acetyltransferase 2	Homo sapiens	211-215
11642327-1	2001	Sulfapyridine (SP) is metabolized by polymorphic N-acetyltransferase 2 (NAT2) [EC 2.3.1.5].	Sulfapyridine	0-13	N-acetyltransferase 2	Homo sapiens	49-70
11642327-1	2001	Sulfapyridine (SP) is metabolized by polymorphic N-acetyltransferase 2 (NAT2) [EC 2.3.1.5].	Sulfapyridine	0-13	N-acetyltransferase 2	Homo sapiens	72-76
11642327-1	2001	Sulfapyridine (SP) is metabolized by polymorphic N-acetyltransferase 2 (NAT2) [EC 2.3.1.5].	Sulfapyridine	15-17	N-acetyltransferase 2	Homo sapiens	49-70
11642327-1	2001	Sulfapyridine (SP) is metabolized by polymorphic N-acetyltransferase 2 (NAT2) [EC 2.3.1.5].	Sulfapyridine	15-17	N-acetyltransferase 2	Homo sapiens	72-76
11642327-2	2001	In this study, the correlation between the NAT2 genotype and the pharmacokinetics of SP after multiple oral dosing of sulfasalazine (SASP) was examined to elucidate the effect of multiple dosing on the predictability of the phenotype by NAT2 genotyping.	Sulfapyridine	85-87	N-acetyltransferase 2	Homo sapiens	43-47
11642327-2	2001	In this study, the correlation between the NAT2 genotype and the pharmacokinetics of SP after multiple oral dosing of sulfasalazine (SASP) was examined to elucidate the effect of multiple dosing on the predictability of the phenotype by NAT2 genotyping.	Sulfapyridine	85-87	aspartic peptidase retroviral like 1	Homo sapiens	133-137
8598465-6	1996	Interestingly, sulfasalazine and sulfapyridine, but not 5-ASA, inhibited Ag-stimulated TNF-alpha released by MC.	Sulfapyridine	33-46	tumor necrosis factor	Rattus norvegicus	87-96
11529938-4	2001	In the present study, we investigated the effect of sulphasalazine and two related compounds - sulphapyridine and 5-aminosalicylic acid - on M phi activation induced by bacterial lipopolysaccharide (LPS) and interferon-gamma (IFN-gamma).	Sulfapyridine	95-109	interferon gamma	Homo sapiens	208-224
10194945-1	1999	Sulfasalazine (SASP), since 60 years standard in the treatment of ulcerative colitis, is a double molecule where 5-aminosalicylic acid (5-ASA) and sulfapyridine (SP) are linked together by an azobond.	Sulfapyridine	147-160	aspartic peptidase retroviral like 1	Homo sapiens	15-19
8960638-4	1996	Lipoxin A4 (LXA4) and the oligopeptide fMLP, activating PMNs by surface receptors, conferred highly significant cytolysis that was dose-dependently reduced when auranofin, gold sodium aurothiomalate (GSTM), and sulfasalazine and its metabolites sulfapyridine and 5-ASA were added to the assay system.	Sulfapyridine	245-258	formyl peptide receptor 1	Homo sapiens	39-43
10602313-3	1999	The aim of the present study was to investigate if sulfasalazine and its colonic metabolites 5-aminosalicylic acid (5ASA) and sulfapyridine affect NF-kappaB/Rel activation and viability of T-lymphocytes.	Sulfapyridine	126-139	nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105	Mus musculus	147-156
10572198-2	1999	Conventional DSC indicated that quenched sulfapyridine exhibited a series of transitions on reheating at 10 degrees C min(-1) which were ascribed to a glass transition (56.9 degrees C), cold crystallisation (103.7 degrees C), a solid-solid transition (131.4 degrees C) and metastable and stable polymorphic melting (177.3 and 186.3 degrees C).	Sulfapyridine	41-54	CD59 molecule (CD59 blood group)	Homo sapiens	118-124
10513809-0	1999	Treatment with sulfasalazine or sulfapyridine, but not 5-aminosalicyclic acid, inhibits basic fibroblast growth factor-induced endothelial cell chemotaxis.	Sulfapyridine	32-45	fibroblast growth factor 2	Homo sapiens	88-118
10513809-6	1999	RESULTS: HMVEC incubated with SSZ or SP exhibited reduced bFGF-induced chemotaxis (59%, [n = 7] and 22%, [n = 3], respectively) (P<0.05).	Sulfapyridine	37-39	fibroblast growth factor 2	Homo sapiens	58-62
10513809-11	1999	SP inhibited cytokine-stimulated HMVEC expression of IL-8 and MCP-1 (P<0.05; [n = 4]).	Sulfapyridine	0-2	C-X-C motif chemokine ligand 8	Homo sapiens	53-57
10513809-11	1999	SP inhibited cytokine-stimulated HMVEC expression of IL-8 and MCP-1 (P<0.05; [n = 4]).	Sulfapyridine	0-2	C-C motif chemokine ligand 2	Homo sapiens	62-67
10513809-13	1999	CONCLUSION: These results demonstrate that SSZ and its metabolite SP may affect the pathogenesis of RA by inhibiting EC chemotaxis, proliferation, tube formation, and expression of sICAM-1, IL-8, and MCP-1.	Sulfapyridine	66-68	C-X-C motif chemokine ligand 8	Homo sapiens	190-194
10513809-13	1999	CONCLUSION: These results demonstrate that SSZ and its metabolite SP may affect the pathogenesis of RA by inhibiting EC chemotaxis, proliferation, tube formation, and expression of sICAM-1, IL-8, and MCP-1.	Sulfapyridine	66-68	C-C motif chemokine ligand 2	Homo sapiens	200-205
8598465-7	1996	Similar results were observed with MC-mediated cytotoxic activity in which sulfasalazine and sulfapyridine, but nor 5-ASA, inhibited MC TNF-alpha-dependent cytotoxicity in a concentration-dependent manner.	Sulfapyridine	93-106	tumor necrosis factor	Rattus norvegicus	136-145
7815356-3	1995	We tested whether SS or its metabolites 5-aminosalicylic acid (5-ASA) and sulfapyridine (SP) inhibited the T-cell activation products interleukin 2 (IL-2) and interleukin 2 receptor alpha-chain (IL-2R alpha).	Sulfapyridine	74-87	interleukin 2	Homo sapiens	134-147
7496871-7	1995	Sulphapyridine significantly reduced TNF and induced IL-1 release in a dose-dependent fashion, but had no significant effect on IL-6 release.	Sulfapyridine	0-14	tumor necrosis factor	Homo sapiens	37-40
7496871-7	1995	Sulphapyridine significantly reduced TNF and induced IL-1 release in a dose-dependent fashion, but had no significant effect on IL-6 release.	Sulfapyridine	0-14	interleukin 1 beta	Homo sapiens	53-57
7736703-6	1995	In the present work, we found that sulphanilamide and some sulphanilamide-related anti-inflammatory drugs such as dapsone, nimesulide and sulphapyridine reduce the availability of HOCl in the extracellular microenvironment of activated neutrophils and prevent the inactivation of alpha 1-antitrypsin by these cells in a dose-dependent manner.	Sulfapyridine	138-152	serpin family A member 1	Homo sapiens	280-299
7736703-10	1995	Therefore, sulphanilamide-related drugs, i.e. dapsone, nimesulide and sulphapyridine, have the potential to reduce the bioavailability of neutrophil-derived HOCl and, in turn, to favour the alpha 1-antitrypsin-dependent control of neutrophil elastolytic activity.	Sulfapyridine	70-84	serpin family A member 1	Homo sapiens	190-209
7815356-3	1995	We tested whether SS or its metabolites 5-aminosalicylic acid (5-ASA) and sulfapyridine (SP) inhibited the T-cell activation products interleukin 2 (IL-2) and interleukin 2 receptor alpha-chain (IL-2R alpha).	Sulfapyridine	74-87	interleukin 2	Homo sapiens	149-153
7815356-3	1995	We tested whether SS or its metabolites 5-aminosalicylic acid (5-ASA) and sulfapyridine (SP) inhibited the T-cell activation products interleukin 2 (IL-2) and interleukin 2 receptor alpha-chain (IL-2R alpha).	Sulfapyridine	74-87	interleukin 2	Homo sapiens	159-172
7815356-3	1995	We tested whether SS or its metabolites 5-aminosalicylic acid (5-ASA) and sulfapyridine (SP) inhibited the T-cell activation products interleukin 2 (IL-2) and interleukin 2 receptor alpha-chain (IL-2R alpha).	Sulfapyridine	74-87	interleukin 2 receptor subunit alpha	Homo sapiens	195-206
7815356-3	1995	We tested whether SS or its metabolites 5-aminosalicylic acid (5-ASA) and sulfapyridine (SP) inhibited the T-cell activation products interleukin 2 (IL-2) and interleukin 2 receptor alpha-chain (IL-2R alpha).	Sulfapyridine	89-91	interleukin 2	Homo sapiens	134-147
7815356-3	1995	We tested whether SS or its metabolites 5-aminosalicylic acid (5-ASA) and sulfapyridine (SP) inhibited the T-cell activation products interleukin 2 (IL-2) and interleukin 2 receptor alpha-chain (IL-2R alpha).	Sulfapyridine	89-91	interleukin 2	Homo sapiens	149-153
7815356-3	1995	We tested whether SS or its metabolites 5-aminosalicylic acid (5-ASA) and sulfapyridine (SP) inhibited the T-cell activation products interleukin 2 (IL-2) and interleukin 2 receptor alpha-chain (IL-2R alpha).	Sulfapyridine	89-91	interleukin 2	Homo sapiens	159-172
1413882-16	1992	N4-lactose conjugates of sulphapyridine, sulphamerazine, sulphathiazole, sulphadimethoxine and sulphaquinoxaline were present in the milk from cows orally dosed with these five sulphonamide drugs.	Sulfapyridine	25-39	Weaning weight-maternal milk	Bos taurus	133-137
1351726-3	1992	Sulphapyridine, the other constituent of SASP, only inhibited production.	Sulfapyridine	0-14	aspartic peptidase retroviral like 1	Homo sapiens	41-45
1673814-5	1991	The effective concentrations of SASP and SP were found to be in the range which can be reached during SASP therapy.	Sulfapyridine	34-36	aspartic peptidase retroviral like 1	Homo sapiens	102-106
1685664-4	1991	Of the metabolites of sulphasalazine investigated, only sulphapyridine was bioactivated by human liver microsomes in the presence of NADPH to a metabolite which caused marked methaemoglobinaemia and a small, but statistically significant degree of mononuclear leucocyte cell death.	Sulfapyridine	56-70	2,4-dienoyl-CoA reductase 1	Homo sapiens	133-138
1673814-7	1991	While nonsteroidal anti-inflammatory drugs, which are used for symptomatic therapy of rheumatoid arthritis, inhibit cyclooxygenase only, SP, the active metabolite of the second line anti-rheumatic drug SASP, inhibits both PG and LT release.	Sulfapyridine	137-139	aspartic peptidase retroviral like 1	Homo sapiens	202-206
1673814-8	1991	Inhibition of LT synthesis by SASP and SP could contribute to the second line efficacy of SASP therapy in rheumatoid arthritis.	Sulfapyridine	32-34	aspartic peptidase retroviral like 1	Homo sapiens	90-94
6121576-6	1982	3 Most of the SASP reaches the colon and is there split by bacteria, forming sulphapyridine (SP) and 5-aminosalicylic acid (5-ASA).	Sulfapyridine	77-91	aspartic peptidase retroviral like 1	Homo sapiens	14-18
1971506-2	1990	The results show that sulphasalazine, and its metabolite sulphapyridine, inhibit neutrophil superoxide production elicited by the receptor mediated stimulus N-formyl-methionyl-leucyl-phenyl-alanine (fMLP) and by the calcium ionophore A23187.	Sulfapyridine	57-71	formyl peptide receptor 1	Homo sapiens	199-203
1970478-2	1990	But there are adverse effects in 20-30% dependent on the serum-level of the resorbed SASP-metabolite sulphapyridine (SP).	Sulfapyridine	101-115	aspartic peptidase retroviral like 1	Homo sapiens	85-89
2902897-5	1988	Administration of SP plus 5-ASA to parallel cultures that were profoundly suppressed by the molecular equivalent amount of SASP resulted in no suppression.	Sulfapyridine	18-20	aspartic peptidase retroviral like 1	Homo sapiens	123-127
2906888-1	1988	Benzalazine (salicylazobenzoic acid, SAB), a 5-azo derivative of 5-aminosalicylic acid, has been designed as a new therapeutic agent for the treatment of inflammatory bowel disease which might lack the frequent side effects caused by the sulfapyridine moiety of the sulfasalazine molecule (SASP).	Sulfapyridine	238-251	SH3 domain binding protein 5	Homo sapiens	37-40
2873245-4	1986	These results suggest that SP is the active moiety of SASP.	Sulfapyridine	27-29	aspartic peptidase retroviral like 1	Homo sapiens	54-58
16867622-4	1986	For the determination of all the main sulphapyridine metabolites the sulphapyridine aglycones were formed after treatment with beta-glucuronidase.	Sulfapyridine	38-52	glucuronidase beta	Homo sapiens	127-145
6186607-9	1983	Studying the effect of the antiinflammatory sulfone compounds dapsone and sulfapyridine on the MPO-mediated histamine release, we show effective inhibition of the histamine release at concentrations of 0.025-0.2 mM of sulfone.	Sulfapyridine	74-87	myeloperoxidase	Homo sapiens	95-98
34850240-8	2022	A core secretory effector molecule profile (IFN-gamma, IL-13, granzyme B and perforin) was identified for sulfapyridine and sulfapyridine hydroxylamine responsive T-cell clones, which proceeded through Pi and hapten mechanisms, respectively.	Sulfapyridine	106-119	interferon gamma	Homo sapiens	44-53
34850240-8	2022	A core secretory effector molecule profile (IFN-gamma, IL-13, granzyme B and perforin) was identified for sulfapyridine and sulfapyridine hydroxylamine responsive T-cell clones, which proceeded through Pi and hapten mechanisms, respectively.	Sulfapyridine	106-119	interleukin 13	Homo sapiens	55-60
34850240-8	2022	A core secretory effector molecule profile (IFN-gamma, IL-13, granzyme B and perforin) was identified for sulfapyridine and sulfapyridine hydroxylamine responsive T-cell clones, which proceeded through Pi and hapten mechanisms, respectively.	Sulfapyridine	106-119	granzyme B	Homo sapiens	62-72
2867770-1	1985	Sulphasalazine (SASP), used in the treatment of inflammatory bowel disease, is split into sulphapyridine (SP) and 5-aminosalicylic acid (5-ASA) in the colon.	Sulfapyridine	90-104	aspartic peptidase retroviral like 1	Homo sapiens	16-20
6121576-7	1982	4 SP is almost completely absorbed and, with its metabolites, is excreted in the urine (SP renal clearance rate 32.1 ml min-1).	Sulfapyridine	2-4	CD59 molecule (CD59 blood group)	Homo sapiens	120-125
6152489-10	1982	The decreased SP and ACSP concentrations seen in active disease may be due to a combination of disease related alterations in either cleavage of SASP or absorption and clearance of SP.	Sulfapyridine	14-16	aspartic peptidase retroviral like 1	Homo sapiens	145-149
33552-2	1978	salicylazosulfapyridine per day the incidence of hemolysis and its relation to the serum level of salicylazosulfapyridine (Salazopyrin, Azulfidline, SASP), free sulfapyridine (SP) and acetyl sulfapyridine (ac-SP) was investigated.	Sulfapyridine	10-23	aspartic peptidase retroviral like 1	Homo sapiens	149-153
20784131-0	1942	Sulphapyridine as an Aid to the Post-operative Treatment of Laryngeal Diphtheria Associated with Measles.	Sulfapyridine	0-14	activation induced cytidine deaminase	Homo sapiens	21-24